CN114158733B - 油凝胶及其制备方法和用途 - Google Patents
油凝胶及其制备方法和用途 Download PDFInfo
- Publication number
- CN114158733B CN114158733B CN202210126905.8A CN202210126905A CN114158733B CN 114158733 B CN114158733 B CN 114158733B CN 202210126905 A CN202210126905 A CN 202210126905A CN 114158733 B CN114158733 B CN 114158733B
- Authority
- CN
- China
- Prior art keywords
- oil
- oleogel
- water
- protein
- structuring agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000001879 gelation Methods 0.000 title description 2
- 239000003921 oil Substances 0.000 claims abstract description 117
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000002245 particle Substances 0.000 claims abstract description 39
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 37
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 34
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 28
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 238000003860 storage Methods 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 235000019198 oils Nutrition 0.000 claims description 115
- 235000018102 proteins Nutrition 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 235000006708 antioxidants Nutrition 0.000 claims description 36
- 239000000725 suspension Substances 0.000 claims description 30
- 108010046377 Whey Proteins Proteins 0.000 claims description 24
- 102000007544 Whey Proteins Human genes 0.000 claims description 24
- 235000021119 whey protein Nutrition 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 21
- 238000000265 homogenisation Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 17
- 230000003405 preventing effect Effects 0.000 claims description 14
- 229940106134 krill oil Drugs 0.000 claims description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 235000021323 fish oil Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 9
- 241000195493 Cryptophyta Species 0.000 claims description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 238000004925 denaturation Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 5
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 201000010041 presbyopia Diseases 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims description 3
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 238000000498 ball milling Methods 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 235000019519 canola oil Nutrition 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 3
- 235000004654 carnosol Nutrition 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 235000010352 sodium erythorbate Nutrition 0.000 claims description 3
- 239000004320 sodium erythorbate Substances 0.000 claims description 3
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 3
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 2
- KJDZDTDNIULJBE-QXMHVHEDSA-N cetoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCCCC(O)=O KJDZDTDNIULJBE-QXMHVHEDSA-N 0.000 claims description 2
- 235000020235 chia seed Nutrition 0.000 claims description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims description 2
- 230000004377 improving vision Effects 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 238000010907 mechanical stirring Methods 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 2
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003656 ricinoleic acid Drugs 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 36
- 230000003647 oxidation Effects 0.000 abstract description 17
- 238000007254 oxidation reaction Methods 0.000 abstract description 17
- 239000008157 edible vegetable oil Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 239000003995 emulsifying agent Substances 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 3
- 239000002562 thickening agent Substances 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 150000002978 peroxides Chemical class 0.000 description 41
- 239000000499 gel Substances 0.000 description 36
- 239000004519 grease Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000000839 emulsion Substances 0.000 description 14
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 229940031439 squalene Drugs 0.000 description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000021120 animal protein Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000000518 rheometry Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 description 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000014594 pastries Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019879 cocoa butter substitute Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000009794 nail development Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- UQDVHJGNIFVBLG-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O UQDVHJGNIFVBLG-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
Abstract
提供了油凝胶及其制备方法和用途。该油凝胶包含60‑90wt%液体油、6‑35wt%结构化剂和4‑15wt%水,其中液体油包含不饱和脂肪酸,且结构化剂是蛋白变性颗粒。本发明的油凝胶作为富含不饱和脂肪酸的抗氧化可食用油脂组合物,组分简单,无需添加额外的稳定剂,避免增稠剂、乳化剂及有机试剂的使用,且具有抗氧化性,有益于产品的长期存放。本发明的油凝胶可以用作口服药物制剂,用于实现多种治疗效用,如调节血脂和/或清理血栓。
Description
技术领域
本发明属于功能食品领域,具体地涉及富含不饱和脂肪酸的功能性组合物,用作口服药物制剂,以改善受试者的身体状态、预防或治疗相关的疾病或病症。
背景技术
不饱和脂肪酸是构成体内脂肪的一种脂肪酸,是人体不可缺少的脂肪酸。不饱和脂肪酸根据双键个数的不同,分为单不饱和脂肪酸和多不饱和脂肪酸两种。鱼油作为不饱和脂肪酸的常见动物来源,含有的不饱和脂肪酸通过与胆固醇结合成酯、进而降解为胆酸排出体外,具有显著的降低血中胆固醇、甘油三酯及升高高密度脂蛋白的作用,可用于抗高血脂。此外,鱼油还具有抗血小板聚集、抗凝血、能预防血栓性疾病的发生等作用。
然而,不饱和脂肪酸的氧化一直是备受关注的重要方向,尤其是在油脂工业、药品及食品行业等方面,都大量涉及到不饱和脂肪酸的氧化问题。现有技术中对于不饱和脂肪酸的氧化往往涉及到抗氧化剂的使用。但出于生产成本和健康目的,本领域中尝试了多种方法来避免抗氧化剂的使用。在这些方法中,使用结构化剂处理不饱和脂肪酸以形成油凝胶成为选项之一。
根据分子量大小的不同,油脂可用结构化剂分为小分子凝胶剂和生物大分子凝胶剂。小分子凝胶剂(单,双硬脂酸甘油酸酯、蜡、卵磷脂、脂肪酸及其衍生物等)通常是通过加热-冷却的方式自组装形成晶体网络结构,进而对液体油进行结构化制备油脂组合物。然而,该类工艺需要加热温度至小分子凝胶剂的熔点以上,较高的操作温度易造成不饱和脂肪酸的氧化酸败。生物大分子,尤其是蛋白质,由于其高营养价值和高消费者接受度,成为油脂结构化剂的最优选择。由于亲水性蛋白质不溶解于油脂,这限制了蛋白质在油脂结构化领域的直接应用。采用蛋白作为结构化剂的油脂结构化通常是采用间接的方式进行制备,主要方法包括Pickering乳液模板法、泡沫模板法和溶剂替代法。
中国发明专利申请(公告号CN107950684)公开了一种以Pickering乳液为模板制备富含不饱和脂肪酸的油脂组合物的方法。该方法先制备明胶-多酚复合物溶液,然后与富含不饱和脂肪酸的植物油剪切均质制备混合乳液,干燥处理并剪切干燥后样品得到固体油脂组合物。该方法需经过均质、干燥、剪切等复杂工序,制备工艺繁琐。该专利最终得到的油脂组合物包含明胶,其由于各种原因而不被消费者所接受,并且包括抗氧化剂多酚以及多糖,形成蛋白-多酚-多糖以颗粒形式吸附在油脂表面。进一步,该方法通过剪切得到油凝胶,粘弹性难以控制,且含油量不高(小于60%)。
中国发明专利申请(公开号CN112063002A)公开了一种米糠蛋白通过泡沫模板法制备多孔材料用于吸附有机溶剂制备有机凝胶,但该凝胶采用有机溶剂,不能满足油凝胶制备的要求;且产品中含有较多空气,不利于油脂的保护。
中国发明专利申请(公开号CN105228461A)公开了一种乙基纤维素连续化制备油脂组合物的方法。该方法利用乙基纤维素高温下溶解的性质,将其与油脂在挤压机中混合,混合物冷却形成油脂组合物。但该方法中挤压机的熔融区温度需高达100~200℃,高温工艺会加速不饱和脂肪酸的氧化。
本领域中仍然需要优化结构化剂以改善现有油凝胶的缺点。
发明内容
针对现有的油凝胶中存在的问题,即含油量低,流变性较差且难以控制,处理过程中由于加热等因素所致的不饱和脂肪酸的氧化,发明人提供了一种新的油凝胶。该油凝胶的制备工艺简单,不包括使不饱和脂肪酸氧化的加热步骤。本发明油凝胶还具备以下特点:含油量高(高于60%),合适的流变性(具有1x103Pa-1x105Pa的储能模量值和具有0.08-0.5的损耗因子)以及抗氧化性高(2.5mmol/kg以下的过氧化值)。
在一方面,本发明提供了一种油凝胶,其包含60-90wt%液体油、6-35wt%结构化剂和4-15wt%水,其中液体油包含不饱和脂肪酸,结构化剂是蛋白变性颗粒,且液体油为连续相。
在一个实施方案中,液体油含量为63-85wt%;和/或结构化剂含量为6-25wt%。
在一个实施方案中,不饱和脂肪酸是单不饱和脂肪酸和多不饱和脂肪酸中的一种或多种。单不饱和脂肪酸可以包括肉豆蔻油酸、棕榈油酸、油酸、反式油酸、蓖麻油酸、芥酸和鲸蜡烯酸中的一种或多种。多不饱和脂肪酸可以包括omega-3和omega-6多不饱和脂肪酸中的一种或多种。
在一个实施方案中,蛋白质是动物蛋白和植物蛋白中的一种或多种。动物蛋白可以包括乳清蛋白、酪蛋白、胶原蛋白和明胶中的一种或多种。
在一个实施方案中,蛋白变性颗粒是通过配制蛋白悬浮液,加热变性,均质并且干燥得到。均质可以是通过机械搅拌均质、超声均质、微射流均质、胶体磨均质、球磨均质中的一种或多种方式进行的。干燥可以是通过真空干燥、真空冷冻干燥、电热鼓风干燥或喷雾干燥中的一种或多种方式进行的。
在一个实施方案中,蛋白悬浮液为2-25wt%的乳清蛋白水悬浮液。
在一个实施方案中,液体油是橄榄油、芥花籽油、花生油、藻油、鱼油、亚麻籽油、紫苏籽油、奇亚籽油和磷虾油中的一种或多种。
在一个实施方案中,油凝胶包含或不包含抗氧化剂。抗氧化剂可以是油溶性抗氧化剂和水溶性抗氧化剂中的一种或多种。
在一个实施方案中,油溶性抗氧化剂为迷迭香酚、鼠尾草酚、芝麻酚、维生素E、丁基羟基茴香醚、二丁羟基甲苯、没食子酸丙酯和叔丁基对苯二酚中的一种或多种,并且水溶性抗氧化剂为维生素C、异抗坏血酸钠、茶多酚、没食子儿茶素没食子酸酯、糖类和糖醇类的一种或多种;其中糖类包括蔗糖;糖醇类为木糖醇、山梨糖醇、赤藓糖醇和麦芽糖醇中的一种或多种。
在一个实施方案中,根据流变仪测定,油凝胶具有以下特征中的一项或多项:
(1) 具有1x103Pa-1x105Pa的储能模量值;
(2) 具有0.08-0.5的损耗因子。
在另一个方面,本发明提供了本发明的油凝胶在食品、保健品或化妆品中的应用,或者本发明的油凝胶在制备用于口服药物制剂中的应用,其中所述口服药物制剂用于以下一项或多项:(1)调节血脂和/或清理血栓;(2) 预防老年痴呆症、营养大脑和/或改善记忆;(3) 预防关节炎、缓解痛风、哮喘,暂时缓解由关节炎引起的肿痛;(4)改善视力和/或防治老花眼; (5) 维护视网膜。
在另一个方面,本发明提供了口服药物制剂,其包含本发明的油凝胶。
在另一个方面,提供了本申请的油凝胶的方法,其包括:
(1) 将结构化剂加入液体油中,混合以得到结构化剂的油相悬浮液;以及
(2) 将水加入结构化剂的油相悬浮液,均质后得到油凝胶。
在一个实施方案中,方法还包括在油相、水相或这两者中分别添加油溶性抗氧化剂、水溶性抗氧化剂或这两者的步骤。
在一个实施方案中,方法不包括对液体油加热的步骤。
本发明的优点包括:
1. 本发明的油凝胶具有高于60%的含油量,满足现有技术中高含油量产品的需要。本发明的油凝胶具有固态/半固态的性状和良好的可塑性、涂抹性和剪切变性等流变特性,可广泛应用于食品体系中。
2. 本发明的油凝胶具有适合的流变性(1x103Pa-1x105Pa的储能模量值和0.08-0.5的损耗因子)。
3. 本发明的油凝胶具有较高的抗氧化性(2.5mmol/kg以下的过氧化值),可以贮存于容易氧化的环境中较长时间。
4. 本发明的油凝胶的制备工艺简单,仅通过均质混合各组分即可获得,无需加热步骤。制备得到不分层、外观均一的富含不饱和脂肪酸的油凝胶。本发明工艺能够进行快速连续化、规模化生产,可通过简单控制过程条件制备粘弹性不同的油脂组合物产品,满足在不同食品、保健食品、医药和化妆品中的应用。
5. 本发明组合物组分简单,可以无需添加额外的稳定剂,避免增稠剂、乳化剂及有机试剂的使用。
附图说明
图1显示了油凝胶的外观照片。A图为++++:透明,不浑浊;B图为+++:半透明,基本不浑浊;C图为++:基本不透明,微浑浊;D图为+:不透明,浑浊。加号越多,油凝胶的外观越有利。油凝胶透明程度与产品结构稳定性有关,越透明表示凝胶越稳定。原理是油凝胶中蛋白质网络的分散程度越高,蛋白聚集体的尺寸就越小,这样光在凝胶中发生散射的角度越小,凝胶也就越透明。
图2显示了染色的油凝胶的显微照片。
图3显示了不同制备方法的油凝胶的水溶性实验一。
图4显示了不同制备方法的油凝胶的水溶性实验二。
具体实施方式
为了进一步理解本发明,下面结合实施例对本发明优选实施方案进行描述,但是应当理解,这些描述只是为了进一步说明本发明的特征和优点,而不是对发明权利要求的限制。本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明内。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。虽然相信本领域普通技术人员充分了解以下术语,但仍陈述以下定义以有助于说明本发明所公开的主题。
如本文所使用,术语“包含”与“包括”、“含有”或“特征在于”同义,并且是包括端点在内或是开放式的,并且不排除额外的未叙述的要素或方法步骤。“包含”是权利要求语言中使用的技术术语,意思指存在所述要素,但也可以增加其它要素并且仍形成在所述权利要求范围内的构造或方法。
如本文所使用,“液体油”是指呈流质状态的油,例如在室内温度呈流质状态的油。液体油可以包括但不限于橄榄油、芥花籽油、花生油、藻油、鱼油、亚麻籽油、紫苏籽油、奇亚籽油和磷虾油。在本文中,按照油凝胶的重量计,液体油的含量是60-90wt%,例如65wt%、70wt%、75wt%、80wt%、85wt%、89wt%。
如本文所使用,“不饱和脂肪酸”指含有1个以上双键的直链脂肪酸,碳链长度通常为18-22个碳原子。不饱和脂肪酸可以包括单不饱和脂肪酸和多不饱和脂肪酸。根据双键的位置及功能又将多不饱和脂肪酸分为omega-6系列和omega-3系列多不饱和脂肪酸。例如,亚油酸和花生四烯酸属于omega-6系列,并且亚麻酸、DHA或EPA属于omega-3系列。优选地,不饱和脂肪酸是omega-3多不饱和脂肪酸。液体油中包含的不饱和脂肪酸的含量可以存在变化。例如,不饱和脂肪酸的含量可以为1%、2%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%或95%或它们之间的任何范围或点值。
如本文所使用,“结构化剂”在本文中是指通过分子之间的强相互作用引起的高分子网络凝聚油脂的成分。结构化剂可以是蛋白变性颗粒。蛋白质可以是动物蛋白和植物蛋白中的一种或多种。例如,动物蛋白是乳清蛋白、酪蛋白、胶原蛋白和明胶中的一种或多种。优选地,结构化剂是蛋白变性颗粒。蛋白变性颗粒可以是通过配制蛋白悬浮液,加热变性,均质并且干燥得到。在一个实施方案中,均质可以是通过机械搅拌均质、超声均质、微射流均质、胶体磨均质、球磨均质中的一种或多种方式进行的。在一个实施方案中,干燥可以是通过真空干燥、真空冷冻干燥、电热鼓风干燥或喷雾干燥中的一种或多种方式进行的。优选地,蛋白悬浮液是乳清蛋白悬浮液,例如2~25wt%的乳清蛋白水悬浮液。例如,乳清蛋白变性颗粒粉可以通过配制浓度范围为2~25%的乳清蛋白悬浮液,磁力搅拌充分溶解后,75~100℃下加热30~100min,制备蛋白变性颗粒液;并且在干燥后得到。在本文中,按照油凝胶的重量计,结构化剂的含量为6-35wt%,例如7 wt%、8wt%、9wt%、10wt%、11wt%、12wt%、13wt%、14wt%、15wt%、16wt%、17wt%、18wt%、19wt%、20wt%、21wt%、22wt%、23wt%、24wt%、25wt%、26wt%、27wt%、28wt%、29wt%、30wt%、31wt%、32wt%、33wt%或34wt%以及其间的任何范围。
如本文所使用,“连续相”指分散体系中分散其他物质的物质。在本文的油凝胶中,连续相可以是液体油。
本发明的油凝胶还可以包含适量的水,例如4-15wt%的水,例如5wt%、6wt%、7 wt%、8wt%、9wt%、10wt%、11wt%、12wt%、13wt%或14wt%以及其间的任何范围。在一个实施方案中,结构化剂与水的重量比为1:3-5:1,例如5:12、1:2、7:12、8:12、9:12、10:12、1:1、20:12、25:12、35:12、40:12。
本发明的油凝胶可以包含或不包含液体油、结构化剂和水以外的其它成分。优选地,本发明的油凝胶不包含其它成分。其它成分可以包括但不限于抗氧化剂、胶凝胶、稳定剂、增稠剂或乳化剂。抗氧化剂可以包括油溶性抗氧化剂和水溶性抗氧化剂中的一种或多种。油溶性抗氧化剂可以包括迷迭香酚、鼠尾草酚、芝麻酚、维生素E、丁基羟基茴香醚、二丁羟基甲苯、没食子酸丙酯和叔丁基对苯二酚中的一种或多种,并且水溶性抗氧化剂可以包括维生素C、异抗坏血酸钠、茶多酚、没食子儿茶素没食子酸酯、糖类和糖醇类的一种或多种。优选地,糖类为蔗糖。优选地,糖醇类为木糖醇、山梨糖醇、赤藓糖醇和麦芽糖醇中的一种或多种。
如本文所使用,“过氧化值”表示油脂和脂肪酸等被氧化程度的一种指标,通常是1千克样品中的活性氧含量,以过氧化物的毫摩尔数表示,用于说明样品是否因已被氧化而变质。一般来说,过氧化值越高其酸败程度越高。过氧化值是食品标准中设定的允许食品氧化的最高限值,超过该值,食品则不合格。如过氧化值超标则说明食品已经变质,而变质的食品可能会对人体产生不良影响。过氧化值可以通过滴定法和比色法来测定,例如如中国食品质量标准GB/T 5009.37-2003食用油卫生标准分析方法中提到的。不同油凝胶的过氧化值标准存在不同。例如,对于DHA藻油,过氧化值/(mmol/kg)应当小于7.5(如中华人民共和国粮食行业标准LS/T 3243-2015规定);对于植物原油食用植物油,过氧化值/(g/100g)应当小于0.25(如食品安全国家标准植物油GB2716-2018规定);对于食用氢化油,过氧化值/(g/100g)应当小于0.1,对于人造奶油,起酥油,代可可脂,植脂奶油,粉末油脂等,过氧化值/(g/100g)应当小于0.13(如食品安全国家标准食用油脂制品GB15196-2015规定)。对于糕点与面包,饼干,方便面,速冻调理制品,过氧化值/(g/100g)应当小于0.25(如相应的食品安全国家标准中规定)。现有技术的产品大多关注于结构化剂的油凝胶成型特性,很少关于形成的油凝胶是否满足过氧化值的食品标准。发明人在长期的研究中发现,本发明的油凝胶可以具备较低的过氧化值,满足国家对各类食品的过氧化值。例如,本发明的油凝胶可以作为营养补充剂应用于糕点与面包。在适当时,也可以作为营养补充剂应用于上述各类以及其它种类的产品中。
在本文中,粘弹性是可以通过多个参数来表征,例如储能模量值(G′),和/或损耗因子(tan δ)。优选地,粘弹性可以通过损耗因子(tan δ)来表征,以表明研究对象呈现固体性质(弹性)或液体性质(粘性)。对于完全弹性材料,tan δ值为0;0< tan δ <1时,研究对象表现出的弹性大于粘性;tan δ = 1时,研究对象处于临界应变下,可以用来衡量延展性;tan δ >1时,研究对象显示出比弹性更多的粘性行为。在本文中,期望的结果是1x103 Pa≤G′≤1x105Pa,0.08≤tan δ≤0.5,得到弹性大于粘性的油凝胶。在本文中,损耗因子以损耗模量值(G″)/储能模量值(G′)来计算,其中储能模量值(G′)和损耗模量值(G″)可以通过流变仪测定。
产品的制备方法
本发明的油凝胶可以通过混合结构化剂,例如乳清蛋白变性颗粒与液体油均质形成油相悬浮液,然后添加水来制备。对于乳清蛋白变性颗粒,可以配制浓度范围为2~25%的乳清蛋白悬浮液,磁力搅拌充分溶解后,75~100℃下加热30~100min,即可制备蛋白变性颗粒液;干燥后得到蛋白变性颗粒粉。可以将6~35%的乳清蛋白变性颗粒与液体油,例如富含Omega-3多不饱和脂肪酸的藻油混合,均质得到乳清蛋白的油相悬浮液,然后,可以在上述悬浮液中加入4~15%的水,然后均质获得本发明的油凝胶。方法可以不包括对液体油加热的步骤。在本文中,加热可以是高于室温加热一段时间,例如于40℃、45℃、50℃、55℃、60℃、65℃、70℃、75℃、80℃、85℃、90℃、95℃、100℃或更高温度加热,例如30分钟、35分钟、40分钟、45分钟、50分钟、55分钟或60分钟或更长时间。
产品的效用
本发明的油凝胶根据所含不饱和脂肪酸的类型可以具备不同的效果。例如,本发明的油凝胶可以包含鱼油、角鲨烯、多烯酸乙酯或月见草油中的一种或多种,并且具备这些成分的功效。本发明的油凝胶可以制备成口服药物制剂,用于实现多种治疗效用。
鱼油是ω-3的常见动物来源,富含对人体有益的必需脂肪酸DHA和EPA。鱼油作为一种功能性油脂,可应用于药品,其主要作用功效有:调节血脂,清理血栓,防止血液凝固,预防脑血栓、脑溢血及中风;预防关节炎、缓解痛风、哮喘,暂时缓解由关节炎引起的肿痛;预防老年痴呆症、营养大脑、改善记忆;改善视力、防治老花眼;维护视网膜。除此之外,还可应用于疾病的辅助治疗,其适用的人群有:有血栓,脑溢血或中风等患病者;三高(高血压、高血脂、高胆固醇)人群;视力衰退有老花趋势者;有心脏病、动脉硬化症状的人群;有关节炎、痛风、哮喘的人群;需防治糖尿病合并症的患者。
角鲨烯是从鲨鱼的肝油中发现的一种天然化合物,具有提高体内超氧化物歧化酶(SOD)活性、增强机体免疫能力、改善性功能、抗衰老、抗疲劳、抗肿瘤等多种生理功能。在海洋鱼油类产品中,角鲨烯是唯一确认有防治肿瘤作用,并被广泛用于肿瘤病人的药物。角鲨烯的主要功效有:保肝作用,促进肝细胞再生并保护肝细胞,从而改善肝脏功能;抗疲劳和增强机体的抗病能力,提高人体免疫功能;保护肾上腺皮的功能,提高应激能力;抗肿瘤,尤其在癌切除外科手术后或采用放化疗时使用,效果显著,其最大的特点是防止癌症向肺部转移;升高白细胞的作用。角鲨烯的应用包括改善免疫系统;调节人的酸碱平衡值(碱性产品);用作抗氧化剂,可有效改善皮肤色泽,缓解牛皮癣和皮炎这类皮肤疾患;有助于治疗心脏病,高血压,低血压,糖尿病,胃病,肾病,结膜炎,脓胸,妇女病,类风湿性关节炎;有助于吃大量油腻食品的人士恢复血液中胆固醇的正常水平;是一种健身滋补品。
多烯酸乙酯是自海洋鱼类提取的鱼油经精制、酯化而得的多不饱和脂肪酸乙酯化的产品。主要成分为二十碳五烯酸乙酯和二十二碳六烯酸乙酯,二者含不饱和键较多。为微黄色至黄色的澄清油状液体,略有鱼腥味。具有降低血清甘油三酯和总胆固醇的作用,用于高脂血症。
月见草油的主要成分有:r-亚麻油酸,镁,锌,铜、维生素C、E、B6、B5。可以调合基础油和精油的油脂,具有多项治疗、美白功能,制成胶囊内服可以治疗心血管疾病,经前症候群,更年期综合症,用在芳香疗法中,可以调和乳液、乳霜,改善湿疹,牛皮癣,帮助伤口愈合,指甲发育,解决头发问题,一般是10%的剂量使用。
以下将参考实施例对本申请进行进一步的详细解释。然而,本领域技术人员应理解,这些实施例仅为了说明的目的提供,而不是意图限制本申请。
实施例
下面将结合实施例对本申请的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本申请,而不应视为限定本申请的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。除非另外指明,所列出的所有量均基于总重的重量百分比描述。本申请不应解释为受限于所述的具体实施例。
1. 制备方法
步骤1:配制浓度范围为2~25%的乳清蛋白悬浮液,磁力搅拌充分溶解后,75~100℃下加热30~100min,即可制备蛋白变性颗粒液;干燥后得到蛋白变性颗粒粉;
步骤2:将6~35%的乳清蛋白变性颗粒与富含Omega-3多不饱和脂肪酸的藻油混合,均质得到乳清蛋白的油相悬浮液;
步骤3:向上述悬浮液中加入4~15%的水,然后均质获得含油量高达60~90%的富含Omega-3多不饱和脂肪酸的油凝胶。
2. 测试方法
①流变性质
采用的仪器:流变仪
测试步骤:采用小振幅振荡剪切分析对油凝胶的流变学性质进行分析。将油凝胶置于流变仪(HAAKE MARS 60)样品台,选用锯齿板(P35TI/SE)进行测试。样品台与平行板的间隙为1 mm。首先在25℃下对样品进行应变扫描,记录储能模量值(G′),损耗模量(G″)和损耗因子(tan δ),用于表征油脂组合物的流变性质。
对于流变测试,储能模量(G′)值可以评价弹性度量或存储能量;损耗模量(G″)的值可以评价粘度量度或耗散能量。损耗因子tan δ=G″/G′。
储能模量(G′)反映了组合物的弹性大小。
粘弹性可以通过损耗因子(tan δ)来表征,以表明研究对象呈现固体性质(弹性)或液体性质(粘性)。对于完全弹性材料,tan δ 值为0;0<tan δ <1时,研究对象表现出的弹性大于粘度;tan δ = 1时,研究对象处于临界应变下,可以用来衡量延展性;tan δ >1时,研究对象显示出比弹性更多的粘性行为。
②氧化性
采用的仪器:酸式滴定管,碘量瓶,旋转蒸发仪
测试步骤:
(1)取样
将制备得到的样品破碎并充分混匀后置于广口瓶中,加入2~3倍样品体积的石油醚,摇匀,充分混合后静置浸提12h以上。经装有无水硫酸钠的漏斗过滤,取滤液,在低于40℃的水浴中,用旋转蒸发仪减压蒸干石油醚,残留物即为待测试样。
(2)样本测定
应避免在阳光直射下进行试样测定。称取试样2g~3g(精确至0.001g),置于250mL碘量瓶中,加入30mL 三氯甲烷-冰乙酸混合液,轻轻振摇使试样完全溶解。准确加入1.00mL饱和碘化钾溶液,塞紧瓶盖,并轻轻振摇0.5min,在暗处放置3min。取出加100mL水,摇匀后立即用硫代硫酸钠标准溶液(过氧化值估计值在5.91mmol/kg及以下时,用0.002mol/L标准溶液;过氧化值估计值大于5.91mmol/kg g时,用0.01mol/L标准溶液)滴定析出的碘,滴定至淡黄色时,加1mL淀粉指示剂,继续滴定并强烈振摇至溶液蓝色消失为终点。同时进行空白试验。空白试验所消耗0.01mo1/L 硫代硫酸钠溶液体积V0 不得超过0.1mL。
(3)分析结果的表述
用1kg样品中活性氧的毫摩尔数表示过氧化值时,按公式:X = (V -V0) x c/(2 xm) x 1000计算。
式中:
X :过氧化值,单位为毫摩尔每千克(mmol/kg);
V:试样消耗的硫代硫酸钠标准溶液体积,单位为毫升(mL);
V0:空白试验消耗的硫代硫酸钠标准溶液体积,单位为毫升(mL);
c:硫代硫酸钠标准溶液的浓度,单位为摩尔每升(mol/L) 。
m:试样质量,单位为克(g);
1000:换算系数。
计算结果以重复性条件下获得的两次独立测定结果的算术平均值表示,结果保留两位有效数字。
评价标准:以过氧化值表征油脂组合物的抗氧化能力;过氧化值越低,则抗氧化性越好。
③外观评价
如图1中所示,A图为++++表示:透明,不浑浊;
B图为+++表示:半透明,基本不浑浊;
C图为++表示:基本不透明,微浑浊;
D图为+表示:不透明,浑浊。
实施例1:油脂组合物的结构表征
1. 根据表1的配方制备油凝胶。具体地,将18wt%的乳清蛋白蛋白变性颗粒加入70wt%富含Omega-3多不饱和脂肪酸的藻油中,混合0.5~3h得到蛋白的油相悬浮液;然后将12wt%纯化水加入到上述油相悬浮液中,均质3~30min后得到所述富含Omega-3多不饱和脂肪酸的油凝胶。
表1:油凝胶的配方
对油凝胶进行了显微观察(染色方式)以进行结构表征:蛋白颗粒在制备过程中使用硫磺素T(Th T)荧光染色;使用 Leica TCS SP5 共聚焦激光扫描显微镜(LeicaMicrosystems Inc., Heidelberg, Germany)捕获蛋白质颗粒或网络的成像,激发波长为458 nm。
图2中显示了油脂组合物中蛋白颗粒形成渗透网络的结果。根据图2中所示,黑色部分为油脂,而蛋白经染色后具有荧光吸收,在激光共聚焦显微镜下呈现绿色亮点。根据显微图片,显示绿色荧光的蛋白颗粒连结、聚集成链状,该结构可使液体油脂凝结成半固态/固态油脂组合物,即油凝胶。该特殊结构的油凝胶可有效阻隔氧气,减缓富含Omega-3多不饱和脂肪酸的油脂的氧化酸败,如下文所示。根据图2可知,在该油凝胶中,藻油为连续相,而蛋白颗粒为分散相。
2. 单,双硬脂酸甘油酸酯结构油脂对比例。
将90wt%藻油与10wt%单,双硬脂酸甘油酯充分混合后,70~100℃下加热30~60min后冷却,即得油脂组合物。
通过加热单,双硬脂酸甘油酯冷却结晶的方式可制得固体/半固体油脂组合物。由于该加热过程会加速富含Omega-3多不饱和脂肪酸的油脂的氧化酸败,通过氧化性测定,过氧化值为5.2mmol/kg。相反,本申请的油凝胶的制备过程不需要加热步骤,避免了加热过程中导致的油脂氧化。
实施例2:不同蛋白变性颗粒添加量的考察
对油凝胶的配方中的乳清蛋白变性颗粒的含量对油凝胶的流变性质和过氧化值进行的评估。具体地,控制藻油和水的质量(分别为70g和12g),改变蛋白变性颗粒的质量(以g计),通过上文描述的方法测定流变性质和过氧化值。表2中显示了结果。
表2:不同蛋白变性颗粒添加量对流变性质和过氧化值的影响
不成型:指制备后的组合物呈液状或明显流动的混悬油液,无法凝结成固态或半固态。
根据表2中显示,蛋白变性颗粒为6~35%时能够制备出油凝胶,在蛋白变性颗粒含量小于6%或大于35%时不能形成油凝胶。制备的油凝胶具有更好的抗氧化性,过氧化值低于2.5mmol/kg,适合于用作食品。发明人发现蛋白变性颗粒对油凝胶的外观有影响。当蛋白变性颗粒含量为10.8%时,油凝胶外观透明、不浑浊,当进一步增加蛋白变性颗粒含量时,油凝胶外观变得逐渐浑浊。
在一定范围6~35%内,随着蛋白微颗粒的含量增加,凝胶强度增加;在超过一定范围后,蛋白微颗粒处于过饱和状态,无法较好分散于油脂中,导致蛋白微颗粒析出。当蛋白变性颗粒:纯化水=3:12或45:12时,不能形成油凝胶。令人惊讶地,随着蛋白变性颗粒:纯化水从3:12增加到25:12时,过氧化值有逐渐降低的趋势,然后从25:12进一步增加到45:12时,过氧化值又会逐渐增加。当蛋白变性颗粒:纯化水为25:12时,油凝胶的过氧化值最低。
实施例3:不同藻油添加量的考察
对油凝胶的配方中的藻油的含量对油凝胶的流变性质和过氧化值进行的评估。选择具有较低过氧化值的组合,蛋白变性颗粒:纯化水为20:12以测定藻油添加量。具体地,控制蛋白变性颗粒和水的质量(分别为20g和12g),改变藻油的质量(以g计),通过上文描述的方法测定流变性质和过氧化值。表3中显示了结果。
表3:不同藻油添加量对流变性质和过氧化值的影响
根据表3可知,藻油为60~90%时能够制备出油脂组合物,且制备的油凝胶具有较好的抗氧化性。随着藻油含量的增加,油凝胶变得更加透明。当蛋白变性颗粒:纯化水为20:12时,藻油含量高达89%。
实施例4:不同水添加量的考察
对油凝胶的配方中的水含量对油凝胶的流变性质和过氧化值进行的评估。具体地,控制蛋白变性颗粒和藻油的质量(分别为20g和70g),改变水的质量(以g计),通过上文描述的方法测定流变性质和过氧化值。表4中显示了结果。
表4:不同水添加量对流变性质和过氧化值的影响
根据表4可知,水为4~15%时能够制备出油脂组合物,且制备的油凝胶具有较好的抗氧化性。令人惊讶地,发明人注意到水含量对于油凝胶的外观有影响。当水含量为4.3%时,油凝胶半透明,基本不浑浊;当水含量增加到15.1%时,油凝胶具备变得更加浑浊的趋势,基本不透明且浑浊。
实施例5:不同油脂来源制备的油凝胶考察
还考察了本发明的油凝胶对不同液体油的适用性。具体地,油凝胶的配方如表5中所示,制备方法与以上所述的方法相同,只是添加不同的液体油。
表5:不同油脂来源制备的油凝胶的流变性质和过氧化值
根据表5可知,除藻油外,亚麻籽油和鱼油也能用同样的方法制备出油脂组合物,且制备的油凝胶具有较好的抗氧化性。
实施例6:添加抗氧化剂的考察
还考察了抗氧化剂的添加对本发明的油凝胶的流变性和过氧化值的影响。具体地,油凝胶的配方如表6中所示,制备方法与以上所述的方法相同,只是额外添加抗氧化剂,维生素C(VC)、蔗糖和赤藓糖醇。结果如表6中所示。
表6:抗氧化剂的添加对本发明的油凝胶的流变性和过氧化值的影响
*样品加速稳定考察条件:温度 40℃,湿度 75%下放置一个月
根据表6可知,本申请的油凝胶比对照1(仅藻油)和对照2(包含藻油和单甘脂),具有更好的抗氧化性。在添加抗氧化剂后,油凝胶抗氧化能力提高,但是即便不添加抗氧化剂,本发明的油凝胶也实现了相同数量级的过氧化值,可以直接用作食品。
对比例7:以油相为连续相的磷虾油油凝胶与以水相为连续相的磷虾油乳液凝胶的性质区别
A:按照表1中组合物的配比,只是用磷虾油替换藻油,制备磷虾油的油凝胶;
B:采用乳清蛋白为凝胶剂,制备磷虾油的乳液凝胶。具体地,磷虾油乳液凝胶如下制备:1、配制8%的乳清蛋白溶液300g;2、水相在18000rpm下高剪切,加入200g磷虾油,保持该转速剪切5min,形成均一的磷虾油乳液;3、85℃下加热30min,再放置于冰水下冷却,即可形成磷虾油乳液凝胶。
分别取A和B两种凝胶各0.5g于50mL 60℃的纯化水中,设定500rpm的转速进行充分搅拌10min,观察对比两种凝胶的状态。
由图3和图4可得,磷虾油凝胶(A管)和乳液凝胶(B管)在外观上虽较为相似,但磷虾油凝胶不溶于水,悬浮于水上,磷虾油乳液凝胶能复溶于水,形成乳液从结构分析,油凝胶的连续相为油脂,而乳液凝胶连续相为水。当采用脂溶性色素分别进行染色时,油凝胶可染色,而乳液凝胶为水包油体系,脂溶性色素无法渗透进去,因此不能染色,具有明显区别。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种油凝胶,其包含63-85wt%液体油、7-32wt%结构化剂和5-15wt%水,其中液体油包含不饱和脂肪酸,结构化剂是蛋白变性颗粒,且液体油为连续相;其中蛋白变性颗粒是通过配制蛋白悬浮液,加热变性,均质并且干燥得到;其中均质是通过机械搅拌均质、超声均质、微射流均质、胶体磨均质、球磨均质中的一种或多种方式进行的;其中干燥是通过真空干燥、真空冷冻干燥、电热鼓风干燥或喷雾干燥中的一种或多种方式进行的;其中蛋白悬浮液为2-25wt%的乳清蛋白水悬浮液;
其中根据流变仪测定,油凝胶具有以下特征:
(1) 具有1x103Pa-1x105Pa的储能模量值;和
(2) 具有0.08-0.5的损耗因子;
所述油凝胶通过如下的方法制备,所述方法包括:
(1) 将结构化剂加入液体油中,混合以得到结构化剂的油相悬浮液;以及
(2) 将水加入结构化剂的油相悬浮液,均质后得到油凝胶;方法无需加热步骤。
2.根据权利要求1所述的油凝胶,其中结构化剂含量为7-25wt%。
3.根据权利要求1所述的油凝胶,其中不饱和脂肪酸是单不饱和脂肪酸和多不饱和脂肪酸中的一种或多种;单不饱和脂肪酸包括肉豆蔻油酸、棕榈油酸、油酸、反式油酸、蓖麻油酸、芥酸和鲸蜡烯酸中的一种或多种;多不饱和脂肪酸包括omega-3和omega-6多不饱和脂肪酸中的一种或多种。
4.根据权利要求1所述的油凝胶,其中液体油是橄榄油、芥花籽油、花生油、藻油、鱼油、亚麻籽油、紫苏籽油、奇亚籽油和磷虾油中的一种或多种。
5.根据权利要求1所述的油凝胶,其包含或不包含抗氧化剂;其中抗氧化剂是油溶性抗氧化剂和水溶性抗氧化剂中的一种或多种。
6.根据权利要求5所述的油凝胶,其中油溶性抗氧化剂为迷迭香酚、鼠尾草酚、芝麻酚、维生素E、丁基羟基茴香醚、二丁羟基甲苯、没食子酸丙酯和叔丁基对苯二酚中的一种或多种,并且水溶性抗氧化剂为维生素C、异抗坏血酸钠、茶多酚、没食子儿茶素没食子酸酯和糖醇类的一种或多种;其中糖醇类为木糖醇、山梨糖醇、赤藓糖醇和麦芽糖醇中的一种或多种。
7.根据权利要求1所述的油凝胶在食品、保健品或化妆品中的应用,或者根据权利要求1所述的油凝胶在制备口服药物制剂中的应用,其中所述口服药物制剂用于以下一项或多项:(1)调节血脂和/或清理血栓;(2) 预防老年痴呆症、营养大脑和/或改善记忆;(3) 预防关节炎、缓解痛风、哮喘,暂时缓解由关节炎引起的肿痛;(4)改善视力和/或防治老花眼;和(5) 维护视网膜。
8.口服药物制剂,其包含根据权利要求1所述的油凝胶。
9.制备权利要求1的油凝胶的方法,其包括:
(1) 将结构化剂加入液体油中,混合以得到结构化剂的油相悬浮液;以及
(2) 将水加入结构化剂的油相悬浮液,均质后得到油凝胶;方法无需加热步骤。
10.根据权利要求9所述的方法,其还包括在油相中添加油溶性抗氧化剂、或在水相中添加水溶性抗氧化剂、或在油相中添加油溶性抗氧化剂和在水相中添加水溶性抗氧化剂的步骤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210126905.8A CN114158733B (zh) | 2022-02-11 | 2022-02-11 | 油凝胶及其制备方法和用途 |
PCT/CN2023/075433 WO2023151653A1 (zh) | 2022-02-11 | 2023-02-10 | 油凝胶及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210126905.8A CN114158733B (zh) | 2022-02-11 | 2022-02-11 | 油凝胶及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114158733A CN114158733A (zh) | 2022-03-11 |
CN114158733B true CN114158733B (zh) | 2022-05-17 |
Family
ID=80489707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210126905.8A Active CN114158733B (zh) | 2022-02-11 | 2022-02-11 | 油凝胶及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114158733B (zh) |
WO (1) | WO2023151653A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114158733B (zh) * | 2022-02-11 | 2022-05-17 | 仙乐健康科技股份有限公司 | 油凝胶及其制备方法和用途 |
CN114917779A (zh) * | 2022-04-08 | 2022-08-19 | 沈阳师范大学 | 一种液体植物油基质毛细悬浮液塑性脂肪及其构建方法 |
CN116268423B (zh) * | 2023-02-28 | 2024-03-22 | 鲁维制药集团有限公司 | 活性成分-蛋白质冷凝胶及其制备方法和应用 |
CN116941771B (zh) * | 2023-08-03 | 2024-05-10 | 中国海洋大学 | 一种具有多重功效的南极磷虾油递送体系及其制备和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009023482A1 (de) * | 2009-06-02 | 2010-12-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Emulsion oder Gel zur Herstellung von Omega-3-Fettsäure-haltigen Nahrungsmitteln |
BR112015031110A2 (pt) * | 2013-06-25 | 2017-07-25 | Nestec Sa | partículas agregadas de proteína do soro do leite e uso das mesmas |
EP3011836A1 (en) * | 2014-10-20 | 2016-04-27 | Stichting Top Institute Food and Nutrition | Protein-stabilised oleogels |
CN108200969B (zh) * | 2016-12-20 | 2021-08-13 | 中粮集团有限公司 | 一种玉米醇溶蛋白含油凝胶及其制备方法 |
WO2020242313A1 (en) * | 2019-05-29 | 2020-12-03 | Wageningen Universiteit | One step procedure for producing a protein oleogel |
US20230181463A1 (en) * | 2020-05-15 | 2023-06-15 | Massachusetts Institute Of Technology | Oleogel and oleopaste compositions and uses thereof |
CN113261594B (zh) * | 2021-05-12 | 2022-01-04 | 华南农业大学 | 一种米糠蛋白油凝胶及其制备方法和应用 |
CN114190443A (zh) * | 2021-11-17 | 2022-03-18 | 华南理工大学 | 一种蛋白凝胶剂制备油凝胶的方法 |
CN114158733B (zh) * | 2022-02-11 | 2022-05-17 | 仙乐健康科技股份有限公司 | 油凝胶及其制备方法和用途 |
-
2022
- 2022-02-11 CN CN202210126905.8A patent/CN114158733B/zh active Active
-
2023
- 2023-02-10 WO PCT/CN2023/075433 patent/WO2023151653A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023151653A9 (zh) | 2023-10-19 |
WO2023151653A1 (zh) | 2023-08-17 |
CN114158733A (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114158733B (zh) | 油凝胶及其制备方法和用途 | |
Ashkar et al. | Impact of different oil gelators and oleogelation mechanisms on digestive lipolysis of canola oil oleogels | |
Zhao et al. | Formation, characterization, and potential food application of rice bran wax oleogels: Expeller-pressed corn germ oil versus refined corn oil | |
Ivanov et al. | Flaxseed additive application in dairy products production | |
EP1843668B1 (en) | Powder compositions | |
Nourbehesht et al. | Investigation of stability, consistency, and oil oxidation of emulsion filled gel prepared by inulin and rice bran oil using ultrasonic radiation | |
Wang et al. | The effects of oil type and crystallization temperature on the physical properties of vitamin C-loaded oleogels prepared by an emulsion-templated approach | |
JP2022058430A (ja) | オメガ3脂肪酸塩を含む組成物を製造する方法 | |
TW201240604A (en) | Palm-based and fractionated oil and fat, oil and fat composition and foods mixed with the same | |
CN109287770B (zh) | 一种富含多酚的固态状茶油及制备方法 | |
CN114304283A (zh) | 一种基于油脂凝胶和水凝胶的食品级双凝胶的制备方法 | |
CN106900881A (zh) | 油包水包油的油脂组合物及其制备方法 | |
Ghorghi et al. | Fabrication of novel hybrid gel based on beeswax oleogel: Application in the compound chocolate formulation | |
JP5039291B2 (ja) | 油脂組成物 | |
Chen et al. | Development and characterization of antioxidant-fortified oleogels by encapsulating hydrophilic tea polyphenols | |
Yang et al. | Effect of the water and oleogelator content on characteristics and stability of BC-loaded oleogel-based emulsion | |
WO2013161346A1 (ja) | 徐放性機能材、その製造方法および健康食品 | |
SK281350B6 (sk) | Potravinársky prípravok na báze rastlinného oleja | |
EP3541195A1 (en) | Dietary margarine composition for puff pastry with reduced saturated fat content | |
CN105558092B (zh) | 低饱和油包水油脂组合物 | |
Li et al. | Novel bigels based on walnut oil oleogel and chitosan hydrogel: Preparation, characterization, and application as food spread | |
Zhu et al. | Development and characterization of novel Lycium barbarum seed oil-based oleogels and their application in functional chocolate | |
JPS5911148A (ja) | 蔗糖グリセリドの新規な流動性調剤、それらの製造方法およびそれらの応用 | |
JP4007715B2 (ja) | 植物ステロール含有組成物 | |
Sengupta et al. | Innovative formulation of oleogels using bioactive compounds and sal starch and characterization of their products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |